These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
623 related articles for article (PubMed ID: 36171009)
21. Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer. Chinchilla-Tábora LM; Montero JC; Corchete LA; González-Morais I; Del Barco Morillo E; Olivares-Hernández A; Rodríguez González M; Sayagués JM; Ludeña MD Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396726 [TBL] [Abstract][Full Text] [Related]
22. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review. Christopoulos P Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058 [TBL] [Abstract][Full Text] [Related]
23. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). Provencio M; Serna-Blasco R; Nadal E; Insa A; García-Campelo MR; Casal Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Calvo V; Martín-López J; García-García F; Casarrubios M; Franco F; Sánchez-Herrero E; Massuti B; Cruz-Bermúdez A; Romero A J Clin Oncol; 2022 Sep; 40(25):2924-2933. PubMed ID: 35576508 [TBL] [Abstract][Full Text] [Related]
24. Tumor mutational load, CD8 Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958 [TBL] [Abstract][Full Text] [Related]
25. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition]. Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489 [TBL] [Abstract][Full Text] [Related]
26. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer. Ma T; Wen T; Cheng X; Wang Y; Wei P; Yang B; Yi L; Wang X; Yan Z; Wang J; Liu Z Lung Cancer; 2022 Oct; 172():43-52. PubMed ID: 35988509 [TBL] [Abstract][Full Text] [Related]
27. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728 [TBL] [Abstract][Full Text] [Related]
29. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
30. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230 [TBL] [Abstract][Full Text] [Related]
31. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694 [TBL] [Abstract][Full Text] [Related]
32. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S Front Immunol; 2022; 13():974581. PubMed ID: 36159860 [TBL] [Abstract][Full Text] [Related]
33. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review. West HJ; Kim JY JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722 [TBL] [Abstract][Full Text] [Related]
34. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC. Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623 [TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring Dai M; Wang N; Xia Q; Liao Y; Cao W; Fan J; Zhou D; Wang S; Nie X Front Immunol; 2023; 14():1258762. PubMed ID: 38235141 [TBL] [Abstract][Full Text] [Related]
36. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845 [TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis. Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945 [TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis. Deng H; Zhao Y; Cai X; Chen H; Cheng B; Zhong R; Li F; Xiong S; Li J; Liu J; He J; Liang W Crit Rev Oncol Hematol; 2022 Feb; 170():103582. PubMed ID: 35031441 [TBL] [Abstract][Full Text] [Related]
39. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Duruisseaux M; Martínez-Cardús A; Calleja-Cervantes ME; Moran S; Castro de Moura M; Davalos V; Piñeyro D; Sanchez-Cespedes M; Girard N; Brevet M; Giroux-Leprieur E; Dumenil C; Pradotto M; Bironzo P; Capelletto E; Novello S; Cortot A; Copin MC; Karachaliou N; Gonzalez-Cao M; Peralta S; Montuenga LM; Gil-Bazo I; Baraibar I; Lozano MD; Varela M; Ruffinelli JC; Palmero R; Nadal E; Moran T; Perez L; Ramos I; Xiao Q; Fernandez AF; Fraga MF; Gut M; Gut I; Teixidó C; Vilariño N; Prat A; Reguart N; Benito A; Garrido P; Barragan I; Emile JF; Rosell R; Brambilla E; Esteller M Lancet Respir Med; 2018 Oct; 6(10):771-781. PubMed ID: 30100403 [TBL] [Abstract][Full Text] [Related]
40. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-small Cell Lung Cancer]. Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]